Our
Science

Professor Thomas Gajewski is Professor in the Departments of Pathology and Medicine at the University of Chicago.  He oversees the melanoma oncology clinic and is the leader of the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center. Prof. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies, and is an author/co-author of over 270 scientific publications in the field. He serves as an editor for Cancer Discovery, Journal for Experimental Medicine, and the Journal for Immunotherapy of Cancer, is on the Program Committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), and is past President of the Society for Immunotherapy of Cancer.

Professor Melero is Professor of Immunology at the Clinic of the University of Navarra and at the Center for Applied Medical Research of the University of Navarra, Pamplona, Spain. His current areas of research are focused on translational research with cell, gene and monoclonal antibody-mediated strategies for cancer immunotherapies. Dr. Melero has been awarded the BIAL Prize of Medicine, the Conde de Cartagena Award from the Royal Academy of Medicine, Doctor Durantez LAIR Foundation Award and a Cancer Research Institute research award. He has served on the advisory boards of Bristol Myers-Squibb, Roche-Genentech, AstraZeneca, Merck Serono and Boehringer Ingelheim.

Dr. Roy S. Herbst is widely recognized for his leadership and expertise in lung cancer treatment and research, particularly for the successful development of novel (immuno)therapies, including gefitinib, cetuximab, bevacizumab and axitinib. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. He currently holds the positions of Ensign Professor of Medicine (Medical Oncology), Chief of Medical Oncology, Deputy Director, and Associate Director of Translational Research at the Yale Cancer Center. He previously served on the boards of the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC), and has been involved with the National Cancer Institute’s Thoracic Malignancy Steering Committee since 2012. Before joining Yale, he was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology at The University of Texas MD Anderson Cancer Center (UT-MDACC). Dr. Herbst holds a PhD from The Rockefeller University and a MS from Harvard University. He completed his fellowships at Brigham and Women’s Hospital and the Dana Farber Cancer Institute, and a residency at Brigham and Women’s Hospital. Dr. Herbst received his MD from Cornell University Medical College and earned a MS and BS degree from Yale University

Professor Andrea Necchi is a medical oncologist specializing in the treatment of urological malignancies. In November 2020, he was appointed Associate Professor of Oncology at Vita-Salute San Raffaele University and Director of Genitourinary Medical Oncology at IRCCS San Raffaele Hospital and Scientific Institute in Milan, Italy. Prof. Necchi currently serves as a board member of the EAU Research Foundation and is an associate member of the ASCO-EAU penile cancer guidelines panel. His team pioneered the use of neoadjuvant immunotherapy in muscle-invasive bladder cancer with the PURE-01 trial. He is the principal investigator of our ongoing GDFATHER-2 trial and several other academic phase 1-2 trials of immuno-oncology combinations in urological malignancies. Prof. Necchi received his MD degree from the University of Milan

Dr. Petros Grivas is board-certified medical oncologist with vast experience and high expertise in genitourinary (GU) cancers. He has had a main role in several clinical trials leading to FDA approval of new drugs for urothelial cancer, including avelumab and Trodelvy®. Dr. Grivas is considered a key opinion, thought leader and international expert, giving lectures in several countries, educating oncologists and other healthcare providers, mentoring numerous trainees, leading large innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research. He is dedicated to personalized and outstanding patient care, efficient clinical operations, and believes in optimal patient-physician relationship as well as community outreach. Dr. Grivas is the Clinical Director of the GU Cancers Program and Professor at the Dept. of Medicine, Division of Hematology Oncology, University of Washington and at the Clinical Research Division at Fred Hutchinson Cancer Center. He received his MD and PhD in Greece in 2005 and 2009, respectively. He completed his Internal Medicine Residency at the Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia) in 2010, and a Hematology/Oncology Fellowship at the University of Michigan (Ann Arbor) in 2013. Dr. Grivas was Clinical Lecturer before he was recruited as Assistant Professor at the Cleveland Clinic (Cleveland)

Professor Alexander Eggermont is General Director of Gustave Roussy Cancer Institute, Professor of Oncology at the Paris-Sud University, and Professor of Oncological Surgery at the Erasmus University of Rotterdam in Holland. He also holds the Honorary Joseph Maisin Honorary Chair of Oncological Surgery at the Louvain Catholic University in Belgium, and an Honorary Doctorate at the University of Essen-Duisburg, Germany. In addition, he serves as the President of the European Academy of Cancer Sciences, and the President of the Cancer Core Europe consortium. In 2015, Prof. Eggermont was elevated to the status of Chevalier of the Légion d’Honneur by the French Ministry of Foreign Affairs and International Development. His research specialty is in immunotherapy, the treatment of melanomas and sarcomas in addition to fundamental research in pathogenesis and immunology of tumors.

Professor Reinhard Dummer is Professor of the University of Zürich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a key thought leader in worldwide cutaneous oncology. Currently, he is heading the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology. Prof. Dummer’s principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas and has published more than 741 scientific publications. He is a founding and Board Member of the European Association of Dermato-Oncology, ESMO, URPP and a member of the German National Academy of Sciences (Leopoldina). Prof. Dummer began his medical education in hematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and Zürich, Switzerland.

Dr. F. Stephen Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber / Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana- Farber Cancer Institute and Professor of Medicine at Harvard Medical School. His internationally recognized research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of ASCO, AACR, the ECOG Melanoma Committee, SITC, the European Academy of Tumor Immunology and a founding member of the Society for Melanoma Research. His clinical investigation efforts have pioneered the use of immune checkpoint blockade and combinatorial approaches to treat cancer.  He has published over 300 peer-reviewed scientific publications including articles in the Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and the New England Journal of Medicine.

Professor Wolf H. Fridman is Professor Emeritus of Immunology at the Paris Descartes University Medical School in Paris, France. He received his MD and PhD degrees from the University of Paris. He has been the founder and first Director of the Cordeliers Research Centre, a joint research structure between INSERM, University Paris Descartes, and University Pierre et Marie Curie.

He was also the Head of the Immunology Laboratory of European Hospital Georges Pompidou in Paris. Prof. Fridman’s current research is focused on the immune response in the tumor microenvironment to control clinical outcomes in cervical cancer. He is a world leader in the field of human tumor immunology and has authored over 480 scientific publications in the field.

Professor Wischhusen is scientific co-founder of CatalYm. He is also the Head of the Section of Experimental Tumor Immunology at the University of Würzburg Medical School, Germany. Prof. Wischhusen’s current research is directed towards tumor-host interactions in ovarian and breast cancer, with a strong focus on tumor-initiating cells and their ability to evade immunosurveillance. Previously, he was a research group leader at the Interdisciplinary Center for Clinical Research in Würzburg. He received his PhD from the University of Tübingen, Germany in the field of molecular neuro-oncology.